Following CTLA-4 treatment, the FDA approved the inhibition of programmed death-1 (PD-1) and its ligand PD-L1 as immune checkpoint inhibitors for metastatic melanoma and lung cancers (10). This evidence concerns the gene PDCD1 and lung cancer.